STING1 and neoplasm: In mouse models, STING agonists synergise with radiotherapy to control local and distant disease and mediate rejection of tumour rechallenge (93, 231) via early T-cell-independent and TNF-α-dependent haemorrhagic necrosis, followed by a later stage of CD8 T-cell-dependent control (93).